Determining the Impact of Histology on the Incidence, Pattern, and Timing of Recurrences in Patients with Renal Cell Carcinoma: A Pooled Analysis from the SORCE and ASSURE Trials
This study evaluates pooled data from large phase 3 trials to precisely delineate relapse patterns for patients with intermediate- and high-risk cell renal cell carcinoma (RCC) according to their histology. The site and timing of first relapse provide useful information to support histology-specific RCC surveillance after nephrectomy. Development of genetic and molecular signatures corresponding to relapses at poor prognosis sites for each histology will individualise follow-up and is the next step.
Authors
- Ruth E. Langley (ORCID: https://orcid.org/0000-0002-9706-016X)
- Mahesh Parmar (ORCID: https://orcid.org/0000-0003-0166-1700)
- Bhavna Oza (ORCID: https://orcid.org/0000-0003-3860-1349)
- Tim Eisen
- Angela Meade (ORCID: https://orcid.org/0000-0001-6424-0554)
- David J. Harrison (ORCID: https://orcid.org/0000-0001-9041-9988)
- Axel Bex (ORCID: https://orcid.org/0000-0002-8499-2662)
- Duncan C. Gilbert (ORCID: https://orcid.org/0000-0003-1859-7012)
- Grant Duncan Stewart (ORCID: https://orcid.org/0000-0003-3188-9140)
- Eleni Frangou (ORCID: https://orcid.org/0000-0002-5978-292X)
Institutions
- University of St Andrews (GB)
- Royal Free London NHS Foundation Trust (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- The Netherlands Cancer Institute (NL)
- MRC Clinical Trials Unit at UCL (GB)
- Oncode Institute (NL)
- Addenbrooke's Hospital (GB)
- University College London (GB)
Publication Details
- Journal
- European Urology Open Science
- Published
- 2025-07-26
- DOI
- https://doi.org/10.1016/j.euros.2025.07.003
- Citations
- 1
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Cancer Research UK
- University College London
- Bayer, United Kingdom
- Medical Research Council
- National Cancer Institute